- Home
- ROIV vs FRT Comparison
ROIV vs FRT Comparison
Compare ROIV & FRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- FRT
- Stock Information
- Founded
- ROIV 2014
- FRT 1962
- Country
- ROIV United Kingdom
- FRT United States
- Employees
- ROIV N/A
- FRT N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- FRT Real Estate Investment Trusts
- Sector
- ROIV Health Care
- FRT Real Estate
- Exchange
- ROIV Nasdaq
- FRT Nasdaq
- Market Cap
- ROIV 8.6B
- FRT 8.2B
- IPO Year
- ROIV N/A
- FRT N/A
- Fundamental
- Price
- ROIV $12.92
- FRT $102.67
- Analyst Decision
- ROIV Strong Buy
- FRT Buy
- Analyst Count
- ROIV 4
- FRT 15
- Target Price
- ROIV $15.50
- FRT $112.60
- AVG Volume (30 Days)
- ROIV 5.2M
- FRT 717.5K
- Earning Date
- ROIV 08-11-2025
- FRT 10-29-2025
- Dividend Yield
- ROIV N/A
- FRT 4.29%
- EPS Growth
- ROIV N/A
- FRT 16.00
- EPS
- ROIV N/A
- FRT 3.96
- Revenue
- ROIV $23,233,000.00
- FRT $1,239,059,000.00
- Revenue This Year
- ROIV N/A
- FRT $5.26
- Revenue Next Year
- ROIV $281.14
- FRT $5.20
- P/E Ratio
- ROIV N/A
- FRT $25.86
- Revenue Growth
- ROIV N/A
- FRT 6.05
- 52 Week Low
- ROIV $8.73
- FRT $80.65
- 52 Week High
- ROIV $13.08
- FRT $118.34
- Technical
- Relative Strength Index (RSI)
- ROIV 73.31
- FRT 69.96
- Support Level
- ROIV $11.85
- FRT $98.42
- Resistance Level
- ROIV $13.08
- FRT $100.77
- Average True Range (ATR)
- ROIV 0.31
- FRT 1.63
- MACD
- ROIV 0.10
- FRT 0.49
- Stochastic Oscillator
- ROIV 89.61
- FRT 97.10
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About FRT Federal Realty Investment Trust
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 103 properties, which includes 27.5 million square feet of retail space and over 3,100 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.